摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

哌啶-3-甲醛 | 353290-29-6

中文名称
哌啶-3-甲醛
中文别名
3-哌啶甲醛
英文名称
piperidine-3-carbaldehyde
英文别名
Piperidin-3-carbaldehyd
哌啶-3-甲醛化学式
CAS
353290-29-6
化学式
C6H11NO
mdl
MFCD03789632
分子量
113.159
InChiKey
GPRQUTDXGQDKEQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    181℃
  • 密度:
    1.037
  • 闪点:
    81℃

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    8
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.833
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090

SDS

SDS:67c815c1305fbf30c846630ff67f27e1
查看

反应信息

  • 作为反应物:
    描述:
    哌啶-3-甲醛 在 sodium tetrahydroborate 、 二碳酸二叔丁酯 作用下, 以 甲醇二氯甲烷 为溶剂, 生成 2-Naphthalen-1-yl-1-[4-[[4-(piperidin-3-ylmethylamino)butylamino]methyl]piperidin-1-yl]ethanone
    参考文献:
    名称:
    Synthesis of polyamine derivatives Having non-hypotensive Ca2+-permeable AMPA receptor antagonist activity
    摘要:
    In order to obtain non-hypotensive and Ca2+-permeable AMPA receptor antagonists, we have synthesized a series of 1,4-bis(4-piperidinylmethyl)diaminobutanes. Compounds 13b, c, f had desirable properties. (C) 2001 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(01)00170-6
  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 作用下, 生成 哌啶-3-甲醛
    参考文献:
    名称:
    Wohl; Losanitsch, Chemische Berichte, 1907, vol. 40, p. 4695
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIMIDINE UTILISÉS COMME INHIBITEURS DE TYROSINE KINASE
    申请人:PRINCIPIA BIOPHARMA INC
    公开号:WO2012158795A1
    公开(公告)日:2012-11-22
    The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.
    本公开提供了一些酪氨酸激酶抑制剂及其药用盐,特别是BLK、BMX、EGFR、HER2、HER4、ITK、Jak3、TEC、Btk和TXK,因此适用于治疗通过抑制酪氨酸激酶可治疗的疾病,如癌症和炎症性疾病,如关节炎等。还提供了含有这些化合物和药用盐的药物组合物以及制备这些化合物和药用盐的方法。
  • Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
    申请人:Perrissoud Daniel
    公开号:US20070037857A1
    公开(公告)日:2007-02-15
    The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).
    本发明提供了一种新型的三唑衍生物,作为生长激素分泌素受体的胃泌素类似物配体,其符合以下公式(I),可用于治疗或预防哺乳动物,尤其是人类,通过GHS受体介导的生理和/或病理条件。本发明还提供了可用于调节这些受体并用于治疗上述疾病的GHS受体拮抗剂和激动剂,特别是生长迟缓、虚弱、短期、中期和/或长期能量平衡的调节;短期、中期和/或长期食物摄入的调节(刺激和/或抑制);脂肪生成、脂肪堆积和/或肥胖;体重增加和/或减少;糖尿病、糖尿病I型、糖尿病II型、肿瘤细胞增殖;炎症、炎症效应、胃术后肠梗阻、术后肠梗阻和/或胃切除(胃泌素替代疗法)。
  • Piperidine derivative and use thereof
    申请人:Shirai Junya
    公开号:US20080275085A1
    公开(公告)日:2008-11-06
    The present invention provides a novel piperidine derivative and a tachykinin receptor antagonist containing same, as well as a compound represented by the formula: wherein R 1 is carbamoylmethyl, methylsulfonylethylcarbonyl and the like; R 2 is methyl or cyclopropyl; R 3 is a hydrogen atom or methyl; R 4 is a chlorine atom or trifluoromethyl; R 5 is a chlorine atom or trifluoromethyl; and a group represented by the formula: is a group represented by the formula: wherein R 6 is a hydrogen atom, methyl, ethyl or isopropyl; R 7 is a hydrogen atom, methyl or a chlorine atom; and R 8 is a hydrogen atom, a fluorine atom, a chlorine atom or methyl; or 3-methylthiophen-2-yl, and a salt thereof.
    本发明提供了一种新颖的哌啶衍生物和含有该衍生物的催吐肽受体拮抗剂,以及由下式表示的化合物: 其中R1为羰胺甲基、甲磺酰乙基羰基等;R2为甲基或环丙基;R3为氢原子或甲基;R4为氯原子或三氟甲基;R5为氯原子或三氟甲基;以及由下式表示的基团: 是由下式表示的基团: 其中R6为氢原子、甲基、乙基或异丙基;R7为氢原子、甲基或氯原子;R8为氢原子、氟原子、氯原子或甲基;或3-甲基噻吩-2-基,并且其盐。
  • [EN] INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER<br/>[FR] DÉRIVÉ D'INDOLE ET USAGE POUR LE TRAITEMENT DU CANCER
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2005118587A1
    公开(公告)日:2005-12-15
    The present invention relates to a compound represented by the formula (I’) wherein A is a benzene ring optionally having substituents, R1, R2a and R3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R1 and R2a may form a ring via X, when R1 and R2a form a ring via X, R1 and R2a are each a bond or a divalent C1-5 acyclic hydrocarbon group optionally having substituents, and X is a bond, an oxygen atom, an optionally oxidized sulfur atom or an imino group optionally having a substituent, provided that R1, R2a and X are not bonds at the same time, or a salt thereof, and an agent for inhibiting kinase (phosphorylation enzyme), which contains this compound or a prodrug thereof. The compound of the present invention has an inhibitory activity against kinase such as a vascular endothelial growth factor receptor (VEGFR) and the like, and is useful as an agent for the prophylaxis or threatment of cancer and the like.
    本发明涉及一种由式(I')表示的化合物,其中A是一个苯环,可选地具有取代基,R1、R2a和R3分别是氢原子,可选地具有取代基的碳氢基团或可选地具有取代基的杂环基团,R1和R2a可以通过X形成环,当R1和R2a通过X形成环时,R1和R2a分别是键或可选地具有取代基的二价C1-5非环烃基团,X是键,氧原子,可选地氧化的硫原子或可选地具有取代基的亚胺基团,前提是R1、R2a和X不同时为键,或其盐,以及含有该化合物或其前药的抑制激酶(磷酸化酶)的药剂。本发明的化合物对激酶如血管内皮生长因子受体(VEGFR)等具有抑制活性,并可用作预防或治疗癌症等疾病的药剂。
  • [EN] COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE<br/>[FR] COMPOSÉ POUR LE TRAITEMENT ET LA PROPHYLAXIE DE LA MALADIE DU VIRUS RESPIRATOIRE SYNCYTIAL
    申请人:HOFFMANN LA ROCHE
    公开号:WO2013020993A1
    公开(公告)日:2013-02-14
    A compound of formula (I), as well as pharmaceutically acceptable salt thereof, wherein R1 to R10, A, Q, X and Y are as defined in description and in claims, can be used as a medicament for the treatment of respiratory syncytial virus.
    式(I)的化合物,以及其药学上可接受的盐,其中R1至R10,A,Q,X和Y如描述和索赔中定义的,可用作治疗呼吸道合胞病毒的药物。
查看更多